Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stageⅢcolon cancer:A meta-analysis

• 作者: Hong-Tao Fu Jia-Xin Fu Jing-Jing Tian Liang Zong Ping Chen Shao-Ling Nie Yan-Yan Tang Ying-Ying Xu
• 来源期刊: 世界荟萃分析杂志
• 学科: 医学
• 关键词: CAPECITABINE PLUS OXALIPLATIN CHEMOTHERAPY Colon cancer META-ANALYSIS Long-term effect
• 年，卷（期）: 2020,（1）
• 页码范围: 27-40
• 页数: 14页
• 分类号: R73

摘要

BACKGROUND Many clinical studies for the long-term survival or efficacy of capecitabine plus oxaliplatin(XELOX)in colon cancer have already been studied,but its clinical benefit is controversial.AIM To evaluate the long-term efficacy of XELOX regimen in comparison with other adjuvant chemotherapy protocols in colon cancer.METHODS By searching the PubMed,EMBASE and Cochrane databases,a total of 12 randomized controlled trials involving 6698 stageⅢcolon cancer cases(XELOX protocol:n=3298 cases;other adjuvant chemotherapy protocol:n=3268 cases)were included.The parameter outcomes included the overall survival and the disease-free survival.The quality control of selected literature was based on the Jadad scale and the GRADE system.RESULTS In comparison to other adjuvant chemotherapy regimen,XELOX regimen showed a better overall survival(odds ratio=1.29,95% confidence interval:1.15-1.44,P<0.0001)and a better disease-free survival(odds ratio=1.32,95%confidence interval:1.18-1.46,P<0.0001)for colon cancer patients,suggesting the XELOX regimen can be a good option for postoperative treatment of stage III colon cancer.CONCLUSION The XELOX regimen can be a preferred option for adjuvant treatment of stageⅢcolon cancer after surgery.